Peptide Therapeutics intermediate
Zavegepant - First-in-Human (NCT02823622)
First-in-human trial of zavegepant for migraine. This peptide or oligopeptide is studied for its biological activity, structure-activity relationships, and p...
By Encyclopeptide Editorial | 1 min read
zavegepant-first-in-human-nct02823622 peptide research
Overview
First-in-human trial of zavegepant for migraine.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “Zavegepant - First-in-Human (NCT02823622)” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Zavegepant - First-in-Human (NCT02823622) with interactive quizzes on Wikipept.
Take a Quiz on Wikipept